6 510(k) Summary of Safety and Effectiveness

This summary of the 510(k) premarket notification for the Concentric Retriever[™] is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

6.1 Manufacturer

Concentric Medical Inc.

2585 Leghorn Street

Mountain View, CA. 94043

Telephone: (650) 938-2100

Registration #: To be obtained

6.2 Contact Person

Linda Bradley

Senior Regulatory Affairs Specialist

6.3 Date Prepared

October 31, 2000

6.4 Classification

Percutaneous Catheter, 21CFR 870.1250 - Class II

6.5 Trade Name

Concentric Retriever[™]

6.6 Generic/Common Name

Percutaneous Catheter

6.7 Predicate Devices

Target Therapeutics® Attracter™ Endovascular Snare (K964210)
Microvena Corporation Amplatz Goose Neck Microsnare™ (K970668)

6.8 Intended Use

The Concentric Retriever is intended for use in the retrieval of foreign bodies located in the coronary, peripheral or neuro vasculature.

6.9 Product Description

The Concentric Retriever consists of a nitinol tapered wire with a helical shaped distal tip. A platinum coil is attached over the helical distal tip. A hydrophilic coating reduces friction during use. A radiopaque distal coil facilitates fluoroscopic visualization.

6.10 Substantial Equivalence

The Concentric Retriever is intended for use in interventional radiological procedures. It is substantially equivalent to other devices currently on the market for use in interventional radiological procedures. The Concentric Retriever is equivalent to the Attracter Endovascular Snare manufactured by Target Therapeutics (K964210) and the Amplatz Goose Neck Microsnare manufactured by Microvena Corporation (K970668). The Concentric Retriever is substantially equivalent to the predicate devices in indications for use, anatomical sites, target population, device description, device operation, use, sterility methods and materials. There are no differences between the predicate devices and the Concentric Retriever that raise any questions of safety and effectiveness.

6.11 Testing in Support of Substantial Equivalence

Performance testing and animal testing have been conducted and the results of the testing verified that the Concentric Retriever performs as designed and is suitable for its intended use.

Page 11



MAY 2 2 2001

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Mr. Kevin F. MacDonald Concentric Medical, Inc. 2585 Leghorn Street Mountain View, CA 94043

Re:

K003410

Concentric RetrieverTM

Regulation Number: 870.1250 Regulatory Class: II (two) Product Code: DQY Dated: February 20, 2001

Received: February 21, 2001

Dear Mr. MacDonald:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish

Page 2 – Mr. Kevin F. MacDonald

further announcements concerning your device in the <u>Federal Register</u>. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4648. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

~James E. Dillard III

Director

Division of Cardiovascular and

Respiratory Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

5 Statement of Indications for Use

INDICATIONS FOR USE

510(k) Number (if known):

K003410

Device Name: Concentric Retriever[™]

Indications for Use:

The Concentric Retriever[™] is indicated for use in the retrieval of foreign bodies in the peripheral, coronary and neuro vasculature.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use (Per 21 CFR 801.109)

OR.

Over-The Counter Use _____(Optional Format 1-2-96)

Division of Cardiovascular & Respiratory Devices